GlassScriptPhysician profile
Sean Foley
NPI 1225769565
$2,626.09
in general payments reported to CMS, 2019-2025
21 companies · $90.99 in 2025
The $90.99 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.68 · 2023: $1,476 · 2024: $1,014 · 2025: $90.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,555 · Education: $25.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,554.98 |
| Education | $25.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $615.37 | 2022-2024 | Xifaxan, Trulance |
| Abbvie INC. | $523.98 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.52 | 2023-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $175.75 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $168.49 | 2024 | Voquezna |
| Genzyme Corporation | $143.33 | 2023-2024 | |
| Pfizer INC. | $139.87 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $115.56 | 2023 | Rebyota, Clenpiq |
| Janssen Biotech, INC. | $87.92 | 2022-2023 | Stelara |
| Intercept Pharmaceuticals, INC. | $77.24 | 2023-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $60.05 | 2023-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $54.20 | 2024 | Bylvay |
| Lilly USA, LLC | $41.60 | 2024 | Omvoh |
| Celgene Corporation | $38.19 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $29.30 | 2023 | Linzess |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $25.43 | 2024 | Zymfentra |
| Alnylam Pharmaceuticals INC. | $23.71 | 2023 | Onpattro |
| Braintree Laboratories, INC. | $21.51 | 2023 | Suflave, Sutab |
| Aimmune Therapeutics, INC. | $21.15 | 2024 | |
| Amgen INC. | $16.36 | 2023 | Amjevita |
| Organon LLC | $13.56 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.